Free Trial

Genmab A/S (GMAB) News Today

Genmab A/S logo
$33.17 +0.42 (+1.28%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$33.41 +0.24 (+0.72%)
As of 10/17/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is Genmab A/S Up Today?

Genmab A/S (NASDAQ:GMAB) shares are trading higher today after the stock hit a new 1‑year high and analysts continue to show overall conviction, but the move is being balanced by fresh downward FY2026 estimate revisions and a notable rise in short interest. Below are the key items investors should know and how they may influence the share price.

Posted 1+ days agoAI Generated. May Contain Errors.

GMAB Latest News

What is HC Wainwright's Estimate for Genmab A/S Q2 Earnings?
Wall Street Zen Downgrades Genmab A/S (NASDAQ:GMAB) to Buy
What is HC Wainwright's Forecast for Genmab A/S Q3 Earnings?
Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next?
HC Wainwright Has Negative Outlook of Genmab A/S Q2 Earnings
FY2026 EPS Estimates for Genmab A/S Cut by Leerink Partnrs
What is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?
Why Genmab Stock Popped on Friday
Leerink Partnrs Comments on Genmab A/S FY2027 Earnings
TD Cowen Remains a Hold on Genmab (GMAB)
Genmab A/S (GMAB) Merus N.V. - M&A Call - Slideshow
Genmab A/S (GMAB) M&A Call Transcript
Genmab Makes A Big Bet With Merus N.V. Acquisition
Major Shareholder Announcement
Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Media Mentions By Week

GMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GMAB
News Sentiment

0.26

0.48

Average
Medical
News Sentiment

GMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GMAB Articles
This Week

33

8

GMAB Articles
Average Week

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:GMAB) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners